Summary
Biogen Inc. (BIIB) filed an 8-K on January 25, 2018, to report its financial results for the fourth quarter and full year ended December 31, 2017. The primary purpose of this filing is to furnish a press release detailing these results, which were issued on the same date. Investors should note that this information, while important for understanding the company's performance, is being furnished and not deemed 'filed' for certain regulatory purposes. The full details of the company's financial performance and operational condition can be found in the accompanying press release furnished as Exhibit 99.1.
Key Highlights
- 1Biogen announced its fourth quarter and full year 2017 financial results on January 25, 2018.
- 2The company furnished a press release as Exhibit 99.1 detailing these results.
- 3The filing pertains to the 'Results of Operations and Financial Condition' (Item 2.02).
- 4This 8-K serves as a notification and provides access to the company's earnings announcement.
- 5The press release is furnished and not deemed filed under Section 18 of the Exchange Act.
- 6Investors are directed to the press release for comprehensive financial data and operational updates.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Biogen Inc.'s financial results for the fourth quarter and the full year ended December 31, 2017, by furnishing a press release that was issued on January 25, 2018.
The detailed financial results and operational information are contained within the press release dated January 25, 2018, which is furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to this press release for specifics.
No, the press release furnished with this 8-K is specifically stated to be furnished, not 'filed,' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not subject the company to the liabilities of that section and is not automatically incorporated into other SEC filings.